VEGFR tyrosine kinase inhibitor

Overview

VEGFR tyrosine kinase inhibitors (VEGFR-TKIs) are a class of targeted anticancer and antiangiogenic therapies designed to inhibit signaling through vascular endothelial growth factor receptors, primarily VEGFR1, VEGFR2, and VEGFR3. By blocking receptor tyrosine kinase activity, these agents reduce VEGF-driven endothelial cell activation, vascular proliferation, and new blood vessel formation, processes that are central to tumor angiogenesis and also relevant to lymphangiogenesis and vascular remodeling in nonmalignant disease.

Clinically, VEGFR-TKIs are used in several solid tumors, including renal cell carcinoma and metastatic colorectal cancer, and are often studied in combination with other modalities such as checkpoint inhibitor therapy, chemotherapy, or other targeted agents. Their biological effects extend beyond direct antiangiogenesis: depending on the receptor subtype and disease context, VEGFR blockade can alter the tumor microenvironment, influence immune-cell infiltration, affect macrophage-associated signaling, and modify vascular permeability and tissue perfusion.

Recent Publications Focus

• Recent work in solid-tumor immunotherapy explored a multitarget switchable CAR-T strategy that combined an anti-Her2 single-chain variable fragment with spliced VEGF-A (VEGF121) to redirect T cells against Her2, VEGFR1, and VEGFR2. This design was intended to enhance CAR-T activity in solid tumors by integrating recognition of Human epidermal growth factor receptor 2 (HER2) with VEGF receptor targeting, thereby broadening tumor engagement through an antibody-ligand motif approach 42349416Jun.

• In diabetic kidney disease, investigators reported that selective VEGFR1 blockade produced renoprotection, whereas inhibition of VEGF-A or VEGFR2 worsened albuminuria. This study highlighted receptor-specific differences within the VEGF pathway and suggested that VEGFR1 may be a more favorable therapeutic target than broader VEGF-A or VEGFR2 inhibition in this setting 42315235Jun.

• In glioma, chronic neoadjuvant VEGFR2 inhibition with DC101 was evaluated as a means of normalizing tumor vasculature before focused ultrasound-mediated small-molecule drug delivery. The authors reported that VEGFR2 blockade narrowed vascular caliber and improved the uniformity of subsequent drug delivery, supporting a vascular-normalization strategy rather than simple vessel suppression 41974212Apr.

• In metastatic colorectal cancer, fruquintinib was described as a highly selective inhibitor of VEGFR1, VEGFR2, and VEGFR3, and a real-world subgroup analysis from China examined its mono- and combination-therapy safety. The publication emphasized its established efficacy in phase III trials and extended interest in how VEGFR-targeted treatment performs in routine clinical practice 42204923May.

• In advanced renal cell carcinoma, one study assessed second-line VEGFR-TKI therapy after first-line nivolumab plus ipilimumab, stratified by early progressive disease status. The analysis focused on the effectiveness of VEGFR-TKI treatment in the post-checkpoint inhibitor setting, reflecting the common sequencing of VEGFR-targeted therapy after nivolumab and ipilimumab 42049357Apr.

• Another renal cell carcinoma study reported that the survival advantage associated with combining immune checkpoint inhibitors and VEGFR-TKIs was greater in clear-cell renal cell carcinoma than in non-clear cell renal cell carcinoma. The reported hazard ratios indicated improved progression-free survival and overall survival with the ICI plus VEGFR-TKI approach compared with dual ICI combinations in this context 41591388Jan.

• In metastatic colorectal cancer, a randomized phase-II trial evaluated surufatinib plus FOLFOX/FOLFIRI versus FOLFOXIRI as second-line therapy. Surufatinib was described as an oral multi-kinase inhibitor targeting VEGFR1-3, FGFR1, and CSF-1R, and the study examined whether adding this VEGFR-targeted agent could enhance chemotherapy efficacy 42421558Jul.

• Research in pulmonary hypertension investigated hypoxia-induced adaptive lymphangiogenesis involving Cd74 and Vegfr3, indicating a role for VEGFR3 signaling in lymphatic remodeling under hypoxic stress. Although not a classic oncology setting, this work reinforces the broader biological importance of VEGFR3 in vascular and lymphatic adaptation 42233213Jun.

• In heart failure models, the role of VEGFR3 signaling was examined in vivo using a VEGFR3 inhibitor in animals treated with Dragon's blood or genistein. The study linked VEGFR3 inhibition to cardiac lymphatic remodeling in pressure overload-induced heart failure, underscoring the receptor’s involvement in lymphatic responses during cardiac disease 41936836Apr.

What Changes, What Holds

1. VEGFR-targeted CAR-T design broadens the class beyond direct kinase inhibition
NEW DIRECTION A switchable CAR-T construct that uses VEGF-A motifs to engage VEGFR1/2 moves VEGFR biology into cell-therapy targeting rather than the small-molecule receptor blockade described in the Overview 42349416Jun. That does not replace VEGFR-TKIs, but it shows the pathway can be exploited as an antigen-recognition axis in solid-tumor immunotherapy. The finding is early and engineered, so it is best read as a new therapeutic direction rather than a change to current VEGFR-TKI use.

2. Receptor-selective VEGFR1 inhibition may be safer than broader VEGF-pathway blockade in kidney disease
NEW DIRECTION Selective VEGFR1 blockade in diabetic kidney disease points to a receptor-specific benefit that sits outside the oncology-focused baseline and complicates the usual assumption that VEGF-pathway inhibition is uniformly suppressive 42315235Jun. Because the Overview does not discuss renal protection, this is not a contradiction; it instead suggests that VEGFR1 may have a distinct disease role from VEGFR2 or VEGF-A in this setting. The result is hypothesis-generating and would need confirmation before it informs practice.

3. VEGFR2 blockade can be used to normalize tumor vessels for drug delivery
NEW DIRECTION Chronic VEGFR2 inhibition in glioma is being used not simply to starve vessels, but to reshape them so later drug delivery becomes more uniform 41974212Apr. That extends the Overview’s antiangiogenic account by emphasizing vascular normalization as a functional goal, not just vessel suppression. It does not overturn established use, but it suggests that timing and dosing of VEGFR2 inhibition may matter for combination strategies that depend on tissue penetration.

4. Fruquintinib’s selective VEGFR profile is reaffirmed in routine colorectal cancer care
REINFORCES Real-world safety data for fruquintinib mainly sharpen the existing picture of VEGFR-TKIs as active agents in metastatic colorectal cancer 42204923May. The paragraph does not introduce a new biological role or challenge the Overview; it supports continued clinical interest in selective VEGFR1/2/3 inhibition in routine practice. The added value is practical rather than conceptual, so it strengthens the baseline without changing it.

5. VEGFR-TKIs remain important after checkpoint inhibitor failure in renal cell carcinoma
REINFORCES Second-line VEGFR-TKI use after nivolumab plus ipilimumab fits squarely within the Overview’s statement that these drugs are used in renal cell carcinoma and often sequenced with checkpoint inhibitors 42049357Apr. The new work refines post-ICI positioning, but it does not alter the established role of VEGFR-targeted therapy. It mainly reinforces that VEGFR-TKIs remain a standard downstream option in this treatment pathway.

6. Combining checkpoint inhibitors with VEGFR-TKIs appears especially effective in clear-cell disease
REINFORCES The reported advantage of ICI plus VEGFR-TKI therapy over dual ICI combinations in clear-cell renal cell carcinoma strengthens the Overview’s point that VEGFR blockade is commonly studied with checkpoint inhibitors 41591388Jan. This is not a new mechanism, but it does suggest that histology influences how much benefit the combination delivers. The contrast with non-clear-cell disease also warns against treating the class effect as uniform across renal cancer subtypes.

7. Adding surufatinib to chemotherapy is another VEGFR-targeted combination strategy in colorectal cancer
REINFORCES A VEGFR-targeted multikinase inhibitor being tested alongside FOLFOX/FOLFIRI extends the established pattern of combining VEGFR-TKIs with chemotherapy in solid tumors 42421558Jul. The paragraph adds a specific regimen, not a new conceptual role for the class. Its significance is that it keeps VEGFR inhibition in the combination-therapy space already described in the Overview, while leaving efficacy and tolerability questions open.

8. VEGFR3 also matters in hypoxia-driven lymphatic remodeling beyond cancer
NEW DIRECTION Adaptive lymphangiogenesis in pulmonary hypertension broadens the Overview’s biology beyond tumor angiogenesis and lymphangiogenesis into hypoxic vascular remodeling in cardiopulmonary disease 42233213Jun. Because the baseline already notes relevance to lymphangiogenesis, this is an extension rather than a contradiction, but it shows VEGFR3 signaling can be engaged in nonmalignant adaptive responses. That widens the receptor’s disease relevance and suggests the pathway may be context-dependent rather than purely pro-tumor.

9. VEGFR3 inhibition may shape cardiac lymphatic remodeling in heart failure
NEW DIRECTION VEGFR3-directed intervention in pressure-overload heart failure adds another non-oncologic role for the receptor, namely lymphatic remodeling in the injured heart 41936836Apr. The Overview does not cover cardiac disease, so this is new territory rather than a challenge to the established anticancer account. It suggests VEGFR3 signaling may be therapeutically relevant in heart failure biology, but the evidence is preclinical and does not yet define whether inhibition is beneficial or harmful in patients.

Overview update candidates: VEGFR1-selective effects in diabetic kidney disease; VEGFR2-mediated vascular normalization for drug delivery; VEGFR3 involvement in hypoxia-driven lymphangiogenesis and cardiac lymphatic remodeling.